Latest From Akriti Seth
Japan’s Nippon Chemiphar has managed to reduce its rate of decline in pharmaceutical sales in the third quarter of FY21, on the back of well-performing recently-launched generics and group-wide structural reforms and cost reductions. The company is making no changes to its full-year forecast.
ANI pharma strengthens leadership team by adding three new executives to accelerate future growth. While Coherus and Xbrane appoint new chief financial officers, Lupin and Beximco hire new independent directors. Sandoz is certified “Global Top Employer 2021” yet again by Top Employers Institute.
Japan’s Towa saw 4.6% growth in domestic sales in the first nine months of FY21, on the back of new launches, as the coronavirus pandemic had only a “minor” effect on its business. But while the firm’s launch schedule for new products remains unaffected so far, the company pointed out that there may be slight delays in product development plans going ahead.
Biocon Biologics has become the first biosimilar insulins company to partner with the International Diabetes Federation to help increase affordable access to insulin worldwide. The partnership was sealed at the start of centenary celebrations of the discovery of insulin.
Medicines for Europe has made a series of recommendations to improve the contribution of generics, biosimilars and value-added medicines to the European Commission’s “Beating Cancer Plan.” The association has offered a checklist of key policies to “ensure equity and quality of cancer care is achieved.”
India’s Alkem has announced growing domestically in its financial third quarter, after seeing a low first quarter due to COVID-19. The company has also reported progress in the international market, after receiving 10 ANDA approvals from the US FDA in Q3 FY21.